Accueil > Actualité
Actualite financiere : Actualite bourse

Pfizer: applies for license for RSV vaccine

( - Pfizer today announced that the US FDA has agreed to grant priority review to a Biologics License Application (BLA) for its respiratory syncytial virus (RSV) vaccine candidate.

The FDA's priority review designation reduces the standard review period for BLAs by four months. The Prescription Drug User Fee Act (PDUFA) deadline for an FDA decision is May 2023.

Without RSV vaccines, older adults remain at risk of disease and potentially serious consequences, hospitalisation and, in some cases, death, Pfizer said.

The submission is based on the results of the RENOIR Phase 3 clinical trial.

Copyright (c) 2022 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.